{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:30:42Z","timestamp":1789115442895,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060302"],"award-info":[{"award-number":["82060302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260325"],"award-info":[{"award-number":["82260325"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["24JRRA923"],"award-info":[{"award-number":["24JRRA923"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Innovation and Development Project of Lanzhou University","award":["lzuyxcx-2022-168"],"award-info":[{"award-number":["lzuyxcx-2022-168"]}]},{"name":"Fundamental Research Funds for the Central Universities of Lanzhou University","award":["lzujbky-2024-oy03"],"award-info":[{"award-number":["lzujbky-2024-oy03"]}]},{"name":"Gansu Province Traditional Chinese Medicine Research Project","award":["GZKZ-2024-29"],"award-info":[{"award-number":["GZKZ-2024-29"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Idiopathic inflammatory myopathy (IIM) is a progressive autoimmune disease characterized by interstitial lung disease (ILD) with limited therapeutics available. Pirfenidone (PFD), a medication utilized for the treatment of idiopathic pulmonary fibrosis, exhibits notable antioxidant, anti-inflammatory, and inhibition of collagen synthesis. This study aims to clarify its efficacy and mechanism in treating IIM-ILD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A murine myositis-associated interstitial lung disease (MAILD) model was used to assess the therapeutic effect of PFD. The serum levels of interleukin\u00a0(IL)-1\u03b2, IL-6, and tumor necrosis factor-\u03b1 (TNF-\u03b1) were detected by enzyme-linked immunosorbent assay (ELISA). Pirfenidone was utilized to disrupt neutrophil extracellular traps (NETs) formation in vitro, and its inhibitory effect on NETs was assessed through immunohistochemistry of citrullinated histone H3 and myeloperoxidase in the lung tissue and the serum cfDNA level in mice. Immunohistochemical and western blot were utilized to examine alterations in epithelial-mesenchymal transition (EMT) and NOD-like receptor protein 3 (NLRP3) inflammasome markers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pirfenidone treatment inhibited pulmonary inflammation and fibrosis in the MAILD model. Pirfenidone intervention reduced NETs formation in vitro. Pirfenidone treatment significantly reduces NETs infiltration in the lung tissue and the level of cfDNA in the serum of mice. Additionally, PFD downregulated EMT and NLRP3-related proteins in vivo. Pirfenidone treatment also notably reduced serum levels of IL-1\u03b2, IL-6, and TNF-\u03b1. After NETs stimulation, A549 cells exhibited EMT and activation of NLRP3 inflammasome. Pirfenidone attenuated EMT in A549 cells and suppressed the activation of NLRP3 inflammasome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pirfenidone alleviates ILD in a murine MAILD model by inhibiting NETs formation and NLRP3 inflammasome activation, suggesting that PFD might be a potential therapeutic agent for IIM-ILD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cei\/uxaf019","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:28:09Z","timestamp":1742718489000},"source":"Crossref","is-referenced-by-count":8,"title":["Pirfenidone alleviates interstitial lung disease in mice by inhibiting neutrophil extracellular trap formation and NLRP3 inflammasome activation"],"prefix":"10.1093","volume":"219","author":[{"given":"Qiyan","family":"Su","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College, Lanzhou University , Lanzhou, Gansu ,","place":["China"]},{"name":"Department of Rheumatology, Lanzhou University Second Hospital , Lanzhou, Gansu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2714-4864","authenticated-orcid":false,"given":"Yingyue","family":"Feng","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Lanzhou University , Lanzhou, Gansu ,","place":["China"]},{"name":"Department of Rheumatology, Lanzhou University Second Hospital , Lanzhou, Gansu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Guo","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Lanzhou University , Lanzhou, Gansu ,","place":["China"]},{"name":"Department of Rheumatology, Lanzhou University Second Hospital , Lanzhou, Gansu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cui","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Lanzhou University , Lanzhou, Gansu ,","place":["China"]},{"name":"Department of Rheumatology, Lanzhou University Second Hospital , Lanzhou, Gansu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cuiying Biomedical Research Center, Lanzhou University Second Hospital , Lanzhou, Gansu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cuiying Biomedical Research Center, Lanzhou University Second Hospital , Lanzhou, Gansu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-1431","authenticated-orcid":false,"given":"Sigong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Lanzhou University , Lanzhou, Gansu ,","place":["China"]},{"name":"Department of Rheumatology, Lanzhou University Second Hospital , Lanzhou, Gansu ,","place":["China"]},{"name":"Gansu Province Clinical Research Center for Rheumatology , Lanzhou, Gansu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"2025042903062537700_CIT0001","doi-asserted-by":"publisher","first-page":"1117071","DOI":"10.3389\/fmed.2023.1117071","article-title":"Myositis interstitial lung disease and autoantibodies","volume":"10","author":"Chaudhry","year":"2023","journal-title":"Front Med"},{"key":"2025042903062537700_CIT0002","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00296-023-05336-z","article-title":"Management of myositis associated interstitial lung disease","volume":"43","author":"Thong","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025042903062537700_CIT0003","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11926-013-0359-6","article-title":"Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis","volume":"15","author":"Kiely","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2025042903062537700_CIT0004","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/cei\/uxad104","article-title":"Neutrophil extracellular traps are involved in the occurrence of interstitial lung disease in a murine experimental autoimmune myositis model","volume":"215","author":"Bai","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"2025042903062537700_CIT0005","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.med.55.091902.103810","article-title":"Mechanisms of pulmonary fibrosis","volume":"55","author":"Thannickal","year":"2004","journal-title":"Annu Rev Med"},{"key":"2025042903062537700_CIT0006","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cei.12319","article-title":"Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications","volume":"177","author":"Zhang","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2025042903062537700_CIT0007","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"2025042903062537700_CIT0008","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/cells10081932","article-title":"A fragile balance: does neutrophil extracellular trap formation drive pulmonary disease progression","volume":"10","author":"Block","year":"2021","journal-title":"Cells"},{"key":"2025042903062537700_CIT0009","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1083\/jcb.201203170","article-title":"Neutrophil extracellular traps: is immunity the second function of chromatin","volume":"198","author":"Brinkmann","year":"2012","journal-title":"J Cell Biol"},{"key":"2025042903062537700_CIT0010","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/jcmm.14858","article-title":"Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway","volume":"24","author":"Zhang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2025042903062537700_CIT0011","doi-asserted-by":"publisher","first-page":"663303","DOI":"10.3389\/fimmu.2021.663303","article-title":"Neutrophil extracellular traps induce the epithelial-mesenchymal transition: implications in post-COVID-19 fibrosis","volume":"12","author":"Pandolfi","year":"2021","journal-title":"Front Immunol"},{"key":"2025042903062537700_CIT0012","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/cei\/uxae028","article-title":"Neutrophil extracellular traps induce pyroptosis of pulmonary microvascular endothelial cells by activating the NLRP3 inflammasome","volume":"217","author":"Zhao","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"2025042903062537700_CIT0013","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12989-016-0162-4","article-title":"The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases","volume":"13","author":"Sayan","year":"2016","journal-title":"Part Fibre Toxicol"},{"key":"2025042903062537700_CIT0014","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/157339710791330740","article-title":"Interstitial lung disease in idiopathic inflammatory myopathy","volume":"6","author":"Saketkoo","year":"2010","journal-title":"Curr Rheumatol Rev"},{"key":"2025042903062537700_CIT0015","doi-asserted-by":"publisher","first-page":"1759720X211060907","DOI":"10.1177\/1759720X211060907","article-title":"Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease","volume":"13","author":"Wilfong","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025042903062537700_CIT0016","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(11)60546-1","article-title":"Pirfenidone for idiopathic pulmonary fibrosis","volume":"377","author":"Bouros","year":"2011","journal-title":"Lancet"},{"key":"2025042903062537700_CIT0017","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2014 Sep 18;371(12):1172]","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2025042903062537700_CIT0018","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025042903062537700_CIT0019","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/nep.12831","article-title":"Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis","volume":"22","author":"Li","year":"2017","journal-title":"Nephrol"},{"key":"2025042903062537700_CIT0020","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","article-title":"Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3\u03b2\/\u03b2-catenin and TGF-\u03b21\/Smad2\/3 signaling pathways","volume":"26","author":"Lv","year":"2020","journal-title":"Mol Med"},{"key":"2025042903062537700_CIT0021","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.molimm.2018.05.003","article-title":"Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation","volume":"99","author":"Li","year":"2018","journal-title":"Mol Immunol"},{"issue":"1","key":"2025042903062537700_CIT0022","doi-asserted-by":"publisher","first-page":"uxae106","DOI":"10.1093\/cei\/uxae106","article-title":"A novel mouse model of myositis-associated interstitial lung disease was established by using TLR9 agonist combined with muscle homogenate","volume":"219","author":"Bai","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"2025042903062537700_CIT0023","doi-asserted-by":"publisher","first-page":"106577","DOI":"10.1016\/j.phrs.2022.106577","article-title":"Fluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway","volume":"187","author":"Xie","year":"2023","journal-title":"Pharmacol Res"},{"key":"2025042903062537700_CIT0024","doi-asserted-by":"publisher","first-page":"108805","DOI":"10.1016\/j.intimp.2022.108805","article-title":"Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway","volume":"109","author":"Zhang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2025042903062537700_CIT0025","doi-asserted-by":"publisher","first-page":"155899","DOI":"10.1016\/j.cyto.2022.155899","article-title":"Pirfenidone mitigates TGF-\u03b21-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model","volume":"154","author":"Layoun","year":"2022","journal-title":"Cytokine"},{"key":"2025042903062537700_CIT0026","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/cei\/uxad059","article-title":"The role of neutrophil extracellular traps and proinflammatory damage-associated molecular patterns in idiopathic inflammatory myopathies","volume":"213","author":"Ma","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2025042903062537700_CIT0027","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2326-6066.CIR-22-0197","article-title":"NET-triggered NLRP3 activation and IL18 release drive oxaliplatin-induced peripheral neuropathy","volume":"10","author":"Lin","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025042903062537700_CIT0028","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ajpath.2022.03.003","article-title":"The inflammasome NLR family pyrin domain-containing protein 3 (NLRP3) as a novel therapeutic target for idiopathic pulmonary fibrosis","volume":"192","author":"Colunga Biancatelli","year":"2022","journal-title":"Am J Pathol"},{"key":"2025042903062537700_CIT0029","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.yexcr.2017.12.013","article-title":"NLRP3 inflammasome inhibition attenuates silica-induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells","volume":"362","author":"Li","year":"2018","journal-title":"Exp Cell Res"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxaf019\/62521437\/uxaf019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxaf019\/62521437\/uxaf019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxaf019\/62521437\/uxaf019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:06:33Z","timestamp":1745910393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxaf019\/8090167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxaf019","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"uxaf019"}}